New drug combo shows promise in liver cancer trial
NCT ID NCT05359861
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This phase 2 trial tested whether adding an experimental drug called SRF388 to a standard two-drug regimen (atezolizumab plus bevacizumab) helps people with advanced liver cancer that hasn't been treated before. The study enrolled 30 adults whose cancer could not be surgically removed and had spread. Researchers compared the triple combination against the standard two drugs plus a placebo to see if it improved progression-free survival and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SRF388 (an experimental drug) combined with atezolizumab (Tecentriq) and bevacizumab (Avastin)
What this could lead to
If it works, this combination could offer a new first-line treatment option for people with advanced liver cancer that cannot be surgically removed.
What could go wrong
This is a small, early-phase trial (30 people) with no results yet. The experimental drug may not improve outcomes over standard therapy, and side effects from the combination could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ajou University Hospital
Gyeonggi-do, 443-721, South Korea
-
Buddhist Tzu Chi General Hospital - Hualien Tzu Chi Medical Center
Hualien City, 970, Taiwan
-
CHA University - Bundang CHA General Hospital (CHA Bundang Medical Center)
Gyeonggi-do, 463-712, South Korea
-
Chang Gung Memorial Hospital - Kaohsiung Branch
Kaohsiung City, Taiwan
-
China Medical University Hospital
Taichung, 40447, Taiwan
-
Chonnam National University (CNU) - Chonnam National University Hwasun Hospital (CNUHH)
Gwangju, 58128, South Korea
-
City of Hope
Duarte, California, 91010, United States
-
Daegu Catholic University Medical Center (DCUMC)
Daegu, 705-718, South Korea
-
E-Da Cancer Hospital
Kaohsiung City, 82445, Taiwan
-
Gangnam Severance Hospital - Cancer Hospital
Seoul, 135-720, South Korea
-
Gold Coast Private Hospital
Southport, 4215, Australia
-
Henry Ford Hospital
Detroit, Michigan, 48202, United States
-
Kaohsiung Medical University - Chung-Ho Memorial Hospital
Kaohsiung City, 807, Taiwan
-
Korea University Medical Center - Korea University Anam Hospital
Seoul, 136-705, South Korea
-
Louisville VA Medical Center - Robley Rex VA Medical Center
Louisville, Kentucky, 40206, United States
-
NYU Langone Medical Center - Laura and Isaac Perlmutter Cancer Center (NYU Cancer Institute (NYUCI))
New York, New York, 10016, United States
-
National Taiwan University Hospital
Taipei, 10002, Taiwan
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
-
Pusan National University Yangsan Hospital
Yangsan, 50612, South Korea
-
Royal Melbourne Hospital
Melbourne, Australia
-
Sarah Cannon Research Institute - Tennessee Oncology
Chattanooga, Tennessee, 37404, United States
-
Sarah Cannon Research Institute - Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
Seoul National University Bundang Hospital
Seongnam, 13620, South Korea
-
Seoul National University Hospital (SNUH) - SMG-SNU Boramae Medical Center
Seoul, 156-707, South Korea
-
Severance Hospital
Seoul, 03722, South Korea
-
St George Hospital -Kogarah
Kogarah, 2217, Australia
-
The Alfred Hospital
Melbourne, 3004, Australia
-
The Catholic University of Korea - St. Vincent's Hospital
Suwon, Gyeonggi-do, 442-723, South Korea
-
University of Arizona Cancer Center - North Campus
Tucson, Arizona, 85719, United States
-
University of Florida Health Science Center - Gainesville
Gainesville, Florida, 32610, United States
-
University of Miami, Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
-
University of Michigan Health System (UMHS)
Ann Arbor, Michigan, 48109, United States
-
University of Oklahoma Health Sciences Center - Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
-
University of Southern California - Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of Ulsan College of Medicine - Asan Medical Center (AMC)
Seoul, 138-736, South Korea
-
Veterans Affairs Ann Arbor Healthcare System
Ann Arbor, Michigan, 48105, United States
-
Veterans Affairs New York Harbor Healthcare System - Manhattan VA Medical Center
New York, New York, 10010, United States